List of Wound Healing Companies in California - 11

Comparative Biosciences Inc., a Genesis Drug Discovery and Development (GD3) Company, a premier preclinical contract research organization (CRO) committed, for the last 20 years, to providing expert high-quality contract research services to all sectors of the biomedical community. Extensive experience in the biotechnology and pharmaceutical industries provides our staff with an exceptional track record in preclinical research and drug development capabilities. Our on-site histology laboratory offers routine histopathology, special stains, immunohistochemistry (IHC), plastics, GLP antibody tissue cross reactivity (TCR), and histomorphometry services with quick turn around times. We also have the benefit of having an on site board-certified pathologist for evaluation and reporting of all the histology work done here.

At Elutia we’re pioneering the future of patient care. Our proprietary drug-eluting biomaterial platforms stand at the forefront of medical innovation.

ENCOLL CORP. is a medical devices company based out of 4576 ENTERPRISE STREET, FREMONT, California, United States.

Heart Hugger is a medical devices company that specializes in post-operative care for cardiac and thoracic surgery patients, focusing on pain management through a unique device.

MediCell Technologies (MCT) believes that stem cells can bring unique and exceptional value to health care.We forms Strategic Partnerships with industry and academia entities to facilitate and accelerate preclinical development of stem cell therapies. We are working to advance the field of stem cell applications. Progenitor Biologics®, LLC and AT Scientific, LLC are wholly owned subsidiaries of MediCell Technologies DefenAge® is a brand of Progenitor Biologics.

SigmaGraft®, based in Fullerton, California, USA, collaborates with the world's leading clinicians and researchers to innovate products and build clinical experience. Our products are registered and sold worldwide, and they include bone grafting products for bone regeneration, membrane products for tissue regeneration, and more.

SomaGenics is a privately held biotech company with offices and laboratories located in Santa Cruz, CA. We specialize in small RNA technologies, including innovative RNAi-based therapeutics using sshRNA molecules, and diagnostics/biomarker detection (NGS, quantitative PCR) of small or fragmented RNA, including microRNA.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2023 Sales: $20.5 billion ● Industry: Medical Instruments & Supplies ● Employees: 52,000 worldwide ● 40 years of sales growth leading up to 2020 ● 44+ Manufacturing and R&D Locations Worldwide ● $1.4 billion spent on research and development in 2023 ● ~12,900 patents owned globally in 2023 ● Products sold in ~75 countries ● Fortune 500 Company ● 7 consecutive years as one of Fortune's World's Best Workplaces Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296

A forward-thinking, medical technology company dedicated to developing life-saving products and therapies that encourage healing, reduce complications of tissue damage and inflammation, prevent infection by drug-resistant bacteria and remove the biofilms in which they thrive. We use the best of nature to solve important, real-time problems.

Telios Pharma, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in developing therapies for mast cell-mediated inflammatory diseases. Founded in 1993, the company focuses on small-molecule drugs and has a team of 51 to 100 employees. Its annual revenue is estimated between $10 million and $25 million. The company's pipeline includes innovative Bruton’s tyrosine kinase (BTK) inhibitors. Notable candidates are TL-925, a topical eye drop for dry eye disease currently in Phase 2 trials, and M-7583, an oral BTK inhibitor for primary myelofibrosis. TL-925 has shown promising results, providing rapid relief from symptoms and significant improvements in clinical measures. Telios Pharma aims to address significant unmet needs in both dry eye disease and myelofibrosis, targeting markets with limited existing therapies.

It’s the Ventris focus on quality, donor selection, tissue recover, and processing protocols that sets us apart. The company is dedicated to providing products that adhere to the strictest current tissue banking and processing standards, with the ultimate goal of an exceptional outcome for the patient. Our line of human allograft products is regulated by the FDA Center for Biologics Evaluation and Research (CBER), which regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps). Ventris adheres to Current Good Tissue Practices, focusing extensively on donor eligibility and the recovery process. Ventris Allograft products are regulated under 21 CFR Part 1270 and 21 CFR Part 1271 and Section 361 of the Public Health Services Act.